Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Potential Support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
---|---|---|---|---|---|---|---|
Organ failure associated with Sepsis | $33B | Completed | Multi-country Phase II ongoing |
Q1 2024 | |||
Advanced-stage soild tumors with peritoneal metastases in combination with chemotherapy |
$4B | Phase I/II ongoing |
|||||
Advanced-stage soild tumors with peritoneal metastases stand-alone, + in combination with anti-PD1 |
$4B | Phase I/II ongoing |
|||||
Pipelinemonimono2023-04-04T17:18:27+03:00